Inventor · disambiguated record
James R. Myette
Also filed as: MYETTE JAMES · MYETTE JAMES R
28 granted patents·13 pending applications·370 citations·filing 2003–2025
97Inventor score
Files withVISTERRA INC23MASSACHUSETTS INST TECHNOLOGY8MOMENTA PHARMACEUTICALS INC4MYETTE JAMES R3COLLINS BRIAN EDWARD1
Top patents by PatentIndex Score
41 records- 0198US7247445B22-O sulfatase compositions and methods of hydrolyzing therewithMASSACHUSETTS INST TECHNOLOGY·Filed 2006·Granted Jul 24, 2007·64 cites·5 claims
- 0297US11136385B2Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody moleculeVISTERRA INC·Filed 2020·Granted Oct 5, 2021·4 cites·38 claims
- 0397US10954296B2Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGAVISTERRA INC·Filed 2020·Granted Mar 23, 2021·4 cites·51 claims
- 0497US9212217B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Dec 15, 2015·14 cites·21 claims
- 0597US7504247B22-O sulfatase compositions and methods of degradation therewithMASSACHUSETTS INST TECHNOLOGY·Filed 2006·Granted Mar 17, 2009·44 cites·32 claims
- 0697US7429474B22-O sulfatase compositions and methods of analyzing therewithMASSACHUSETTS INST TECHNOLOGY·Filed 2006·Granted Sep 30, 2008·44 cites·25 claims
- 0797US7396824B22-O sulfatase nucleic acid compositionsMASSACHUSETTS INST TECHNOLOGY·Filed 2006·Granted Jul 8, 2008·50 cites·20 claims
- 0896US10968270B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 6, 2021·3 cites·30 claims
- 0996US9365639B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Jun 14, 2016·9 cites·30 claims
- 1096US7270815B22-O sulfatase compositions and related methodsMASSACHUSETTS INST TECHNOLOGY·Filed 2004·Granted Sep 18, 2007·63 cites·9 claims
- 1194US7695711B2Δ 4,5 glycuronidase nucleic acid compositionsMASSACHUSETTS INST TECHNOLOGY·Filed 2006·Granted Apr 13, 2010·16 cites·8 claims
- 1293US10385123B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2018·Granted Aug 20, 2019·8 cites·30 claims
- 1392US10155806B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2016·Granted Dec 18, 2018·4 cites·30 claims
- 1492US7951560B2Delta 4,5 glycuronidase compositions and methods related theretoMASSACHUSETTS INST TECHNOLOGY·Filed 2009·Granted May 31, 2011·13 cites·18 claims
- 1591US2025066464A1Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2024·Application pending·0 cites
- 1689US7842492B2Compositions of and methods of using sulfatases from flavobacterium heparinumMASSACHUSETTS INST TECHNOLOGY·Filed 2008·Granted Nov 30, 2010·11 cites·5 claims
- 1789US2024425569A1Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 1888US11059883B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2018·Granted Jul 13, 2021·2 cites·30 claims
- 1987US10981982B2Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 20, 2021·1 cites·48 claims
- 2084US8846363B2Compositions of and methods of using sulfatases from Flavobacterium heparinumMYETTE JAMES R·Filed 2010·Granted Sep 30, 2014·10 cites·31 claims
- 2180US12091451B2Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2021·Granted Sep 17, 2024·0 cites·18 claims
- 2278US12054539B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2021·Granted Aug 6, 2024·0 cites·20 claims
- 2377US9921210B2High mannose glycansCOLLINS BRIAN EDWARD·Filed 2011·Granted Mar 20, 2018·2 cites·12 claims
- 2477US7767420B2Heparan sulfate glycosaminoglycan lyase and uses thereofMOMENTA PHARMACEUTICALS INC·Filed 2005·Granted Aug 3, 2010·2 cites·9 claims
- 2577US7691612B2Heparan sulfate glycosaminoglycan lyase and uses thereofMOMENTA PHARMACEUTICALS INC·Filed 2006·Granted Apr 6, 2010·1 cites·14 claims
- 2676US11945868B2Antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2018·Granted Apr 2, 2024·1 cites·37 claims
- 2774US2025043014A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2873US2024301065A1Antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2970US2024092921A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2023·Application pending·0 cites
- 3070US2019330326A1Antibody molecules to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2019·Application pending·0 cites
- 3167US7888072B2Heparan sulfate glycosaminoglycan lyase and uses thereofMOMENTA PHARMACEUTICALS INC·Filed 2009·Granted Feb 15, 2011·0 cites·8 claims
- 3267US2025382379A1Humanized antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3364US12338291B2Humanized antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2020·Granted Jun 24, 2025·0 cites·21 claims
- 3463US2017145086A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2016·Application pending·0 cites
- 3559US2023348614A1Engineered antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2022·Application pending·0 cites
- 3656US2008171375A1Heparan Sulfate Glycosaminoglycan Lyase and Uses ThereofMOMENTA PHARMACEUTICALS INC A·Filed 2007·Application pending·0 cites
- 3754US7691613B2Glycosaminoglycan lyase IV and uses thereofMOMENTA PHARMACEUTICALS INC·Filed 2007·Granted Apr 6, 2010·0 cites·10 claims
- 3853US2005214276A9Delta 4, 5 glycuronidase and uses thereofMYETTE JAMES R·Filed 2003·Application pending·0 cites
- 3953US2021340266A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2021·Application pending·0 cites
- 4049US2012045425A1Delta 4, 5 glycuronidase compositions and methods related theretoMYETTE JAMES R·Filed 2011·Application pending·0 cites
- 4144US8198050B2Heparan sulfate glycosaminoglycan lyase and uses thereofMYETTE JAMES·Filed 2010·Granted Jun 12, 2012·0 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →